메뉴 건너뛰기




Volumn 129, Issue 4, 2012, Pages

Omalizumab and the risk of malignancy: Results from a pooled analysis

Author keywords

allergy; anti IgE; Asthma; IgE; malignancy; omalizumab; pooled analysis

Indexed keywords

OMALIZUMAB; PLACEBO;

EID: 84862820922     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.01.033     Document Type: Article
Times cited : (146)

References (79)
  • 1
    • 77952118055 scopus 로고    scopus 로고
    • European Medicines Evaluation Agency Available at:. Accessed April 19, 2011
    • European Medicines Evaluation Agency. Omalizumab (XOLAIR). Summary of product characteristics. Available at: www.ema.europa.eu. Accessed April 19, 2011.
    • Omalizumab (XOLAIR). Summary of Product Characteristics
  • 2
    • 84876873428 scopus 로고    scopus 로고
    • Novartis US and Genentech Available at:. Accessed June 26, 2010
    • Novartis US and Genentech. Omalizumab (Xolair) label. Available at: www.gene.com. Accessed June 26, 2010.
    • Omalizumab (Xolair) Label
  • 3
    • 0034907372 scopus 로고    scopus 로고
    • Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    • W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
    • (2001) J Allergy Clin Immunol , vol.108 , pp. 184-190
    • Busse, W.1    Corren, J.2    Lanier, B.Q.3    McAlary, M.4    Fowler-Taylor, A.5    Cioppa, G.D.6
  • 6
    • 1242341925 scopus 로고    scopus 로고
    • Anti-IgE monoclonal antibody, omalizumab: A new treatment for allergic asthma
    • K.F. Chung Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma Expert Opin Pharmacother 5 2004 439 446
    • (2004) Expert Opin Pharmacother , vol.5 , pp. 439-446
    • Chung, K.F.1
  • 8
    • 0035262324 scopus 로고    scopus 로고
    • Anti-immunoglobulin e for the treatment of allergic disease
    • W. Busse, and W. Neaville Anti-immunoglobulin E for the treatment of allergic disease Curr Opin Allergy Clin Immunol 1 2001 105 108
    • (2001) Curr Opin Allergy Clin Immunol , vol.1 , pp. 105-108
    • Busse, W.1    Neaville, W.2
  • 9
    • 34548479249 scopus 로고    scopus 로고
    • CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment
    • A. Nopp, S.G. Johansson, J. Ankerst, M. Palmqvist, and H. Oman CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment Allergy 62 2007 1175 1181
    • (2007) Allergy , vol.62 , pp. 1175-1181
    • Nopp, A.1    Johansson, S.G.2    Ankerst, J.3    Palmqvist, M.4    Oman, H.5
  • 10
    • 33749325937 scopus 로고    scopus 로고
    • Clinical data do not suggest a causal relationship between omalizumab therapy and cancer
    • C. Fernandez, W. Busse, C. Reisner, and N. Gupta Clinical data do not suggest a causal relationship between omalizumab therapy and cancer Proc Am Thorac Soc 2 2005 A359
    • (2005) Proc Am Thorac Soc , vol.2 , pp. 359
    • Fernandez, C.1    Busse, W.2    Reisner, C.3    Gupta, N.4
  • 11
    • 0027318539 scopus 로고
    • Cancer risk in asthmatic subjects selected from hospital discharge registry
    • B. Kallen, J. Gunnarskog, and T.B. Conradson Cancer risk in asthmatic subjects selected from hospital discharge registry Eur Respir J 6 1993 694 697
    • (1993) Eur Respir J , vol.6 , pp. 694-697
    • Kallen, B.1    Gunnarskog, J.2    Conradson, T.B.3
  • 12
    • 33745508753 scopus 로고    scopus 로고
    • Atopic diseases, immunoglobulin e and risk of cancer of the prostate, breast, lung and colorectum
    • H. Wang, D. Rothenbacher, M. Low, C. Stegmaier, H. Brenner, and T.L. Diepgen Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum Int J Cancer 119 2006 695 701
    • (2006) Int J Cancer , vol.119 , pp. 695-701
    • Wang, H.1    Rothenbacher, D.2    Low, M.3    Stegmaier, C.4    Brenner, H.5    Diepgen, T.L.6
  • 14
    • 0028818749 scopus 로고
    • A prospective study of cancer incidence in a cohort examined for allergy
    • N.E. Eriksson, A. Holmen, B. Hogstedt, Z. Mikoczy, and L. Hagmar A prospective study of cancer incidence in a cohort examined for allergy Allergy 50 1995 718 722
    • (1995) Allergy , vol.50 , pp. 718-722
    • Eriksson, N.E.1    Holmen, A.2    Hogstedt, B.3    Mikoczy, Z.4    Hagmar, L.5
  • 15
    • 0026649329 scopus 로고
    • Allergy and cancer: Organ site-specific results from the Adventist Health Study
    • P.K. Mills, W.L. Beeson, G.E. Fraser, and R.L. Phillips Allergy and cancer: organ site-specific results from the Adventist Health Study Am J Epidemiol 136 1992 287 295
    • (1992) Am J Epidemiol , vol.136 , pp. 287-295
    • Mills, P.K.1    Beeson, W.L.2    Fraser, G.E.3    Phillips, R.L.4
  • 18
    • 79955406449 scopus 로고    scopus 로고
    • Safety of omalizumab in asthma
    • R.A. Tan, and J. Corren Safety of omalizumab in asthma Expert Opin Drug Saf 10 2011 463 471
    • (2011) Expert Opin Drug Saf , vol.10 , pp. 463-471
    • Tan, R.A.1    Corren, J.2
  • 20
    • 20044368243 scopus 로고    scopus 로고
    • The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
    • J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, and S. Wenzel The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
    • (2005) Allergy , vol.60 , pp. 302-308
    • Bousquet, J.1    Cabrera, P.2    Berkman, N.3    Buhl, R.4    Holgate, S.5    Wenzel, S.6
  • 21
    • 77952505549 scopus 로고    scopus 로고
    • Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
    • M. Kulus, J. Hebert, E. Garcia, T.A. Fowler, V.C. Fernandez, and M. Blogg Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma Curr Med Res Opin 26 2010 1285 1293
    • (2010) Curr Med Res Opin , vol.26 , pp. 1285-1293
    • Kulus, M.1    Hebert, J.2    Garcia, E.3    Fowler, T.A.4    Fernandez, V.C.5    Blogg, M.6
  • 22
    • 77955663329 scopus 로고    scopus 로고
    • Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data
    • M. Molimard, R. Buhl, R. Niven, V. Le Gros, A. Thielen, and J. Thirlwell Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data Respir Med 104 2010 1381 1385
    • (2010) Respir Med , vol.104 , pp. 1381-1385
    • Molimard, M.1    Buhl, R.2    Niven, R.3    Le Gros, V.4    Thielen, A.5    Thirlwell, J.6
  • 23
    • 71249102935 scopus 로고    scopus 로고
    • Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
    • B. Lanier, T. Bridges, M. Kulus, A.F. Taylor, I. Berhane, and C.F. Vidaurre Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J Allergy Clin Immunol 124 2009 1210 1216
    • (2009) J Allergy Clin Immunol , vol.124 , pp. 1210-1216
    • Lanier, B.1    Bridges, T.2    Kulus, M.3    Taylor, A.F.4    Berhane, I.5    Vidaurre, C.F.6
  • 24
    • 79953737882 scopus 로고    scopus 로고
    • Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
    • J. Bousquet, Z. Siergiejko, E. Swiebocka, M. Humbert, K.F. Rabe, and N. Smith Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 2011 671 678
    • (2011) Allergy , vol.66 , pp. 671-678
    • Bousquet, J.1    Siergiejko, Z.2    Swiebocka, E.3    Humbert, M.4    Rabe, K.F.5    Smith, N.6
  • 25
    • 0034881877 scopus 로고    scopus 로고
    • The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
    • M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2001 254 261
    • (2001) Eur Respir J , vol.18 , pp. 254-261
    • Soler, M.1    Matz, J.2    Townley, R.3    Buhl, R.4    O'Brien, J.5    Fox, H.6
  • 27
    • 79955751312 scopus 로고    scopus 로고
    • Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial
    • N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, and J. Zhu Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial Ann Intern Med 154 2011 573 582
    • (2011) Ann Intern Med , vol.154 , pp. 573-582
    • Hanania, N.A.1    Alpan, O.2    Hamilos, D.L.3    Condemi, J.J.4    Reyes-Rivera, I.5    Zhu, J.6
  • 28
    • 11144356805 scopus 로고    scopus 로고
    • Efficacy and safety of a recombinant anti-immunoglobulin e antibody (omalizumab) in severe allergic asthma
    • S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lotvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
    • (2004) Clin Exp Allergy , vol.34 , pp. 632-638
    • Holgate, S.T.1    Chuchalin, A.G.2    Hebert, J.3    Lotvall, J.4    Persson, G.B.5    Chung, K.F.6
  • 29
    • 20044362008 scopus 로고    scopus 로고
    • Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
    • M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
    • (2005) Allergy , vol.60 , pp. 309-316
    • Humbert, M.1    Beasley, R.2    Ayres, J.3    Slavin, R.4    Hebert, J.5    Bousquet, J.6
  • 30
    • 31844443695 scopus 로고
    • The environment and disease: Association or causation?
    • A.B. Hill The environment and disease: association or causation? Proc R Soc Med 58 1965 295 300
    • (1965) Proc R Soc Med , vol.58 , pp. 295-300
    • Hill, A.B.1
  • 31
    • 67651160606 scopus 로고    scopus 로고
    • The role of causal criteria in causal inferences: Bradford Hill's "aspects of association"
    • A.C. Ward The role of causal criteria in causal inferences: Bradford Hill's "aspects of association" Epidemiol Perspect Innov 6 2009 2
    • (2009) Epidemiol Perspect Innov , vol.6 , pp. 2
    • Ward, A.C.1
  • 33
    • 0013401756 scopus 로고    scopus 로고
    • National Cancer Institute Available at:. Accessed November 10, 2011
    • National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/csr/1975-2008/browse-csr.php?section= 2&page=sect-02-table.07.html. Accessed November 10, 2011.
    • Surveillance Epidemiology and End Results
  • 34
    • 85058204664 scopus 로고    scopus 로고
    • Omalizumab and malignancy: Interim results from the EXCELS study
    • M. Eisner, M. Miller, W. Chou, A. Rahmaoui, and M. Bradley Omalizumab and malignancy: interim results from the EXCELS study Eur Respir J 38 suppl 55 2011 A3954
    • (2011) Eur Respir J , vol.38 , Issue.SUPPL. 55 , pp. 3954
    • Eisner, M.1    Miller, M.2    Chou, W.3    Rahmaoui, A.4    Bradley, M.5
  • 35
    • 0035915364 scopus 로고    scopus 로고
    • Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial
    • T.B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, and M. Watrous Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial JAMA 286 2001 2956 2967
    • (2001) JAMA , vol.286 , pp. 2956-2967
    • Casale, T.B.1    Condemi, J.2    Laforce, C.3    Nayak, A.4    Rowe, M.5    Watrous, M.6
  • 36
    • 0242606440 scopus 로고    scopus 로고
    • Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis
    • A. Nayak, T. Casale, S.D. Miller, J. Condemi, M. McAlary, and A. Fowler-Taylor Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis Allergy Asthma Proc 24 2003 323 329
    • (2003) Allergy Asthma Proc , vol.24 , pp. 323-329
    • Nayak, A.1    Casale, T.2    Miller, S.D.3    Condemi, J.4    McAlary, M.5    Fowler-Taylor, A.6
  • 38
    • 0034907372 scopus 로고    scopus 로고
    • Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    • W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
    • (2001) J Allergy Clin Immunol , vol.108 , pp. 184-190
    • Busse, W.1    Corren, J.2    Lanier, B.Q.3    McAlary, M.4    Fowler-Taylor, A.5    Cioppa, G.D.6
  • 39
    • 0034881877 scopus 로고    scopus 로고
    • The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published erratum appears in Eur Respir J 2001;18:739-40]
    • M. Solr, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published erratum appears in Eur Respir J 2001;18:739-40] Eur Respir J 18 2001 254 261
    • (2001) Eur Respir J , vol.18 , pp. 254-261
    • Solr, M.1    Matz, J.2    Townley, R.3    Buhl, R.4    O'Brien, J.5    Fox, H.6
  • 40
    • 0035434688 scopus 로고    scopus 로고
    • Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab)
    • E36
    • H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, and M. McAlary Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
    • (2001) Pediatrics , vol.108
    • Milgrom, H.1    Berger, W.2    Nayak, A.3    Gupta, N.4    Pollard, S.5    McAlary, M.6
  • 41
    • 0043240429 scopus 로고    scopus 로고
    • Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma
    • W. Berger, N. Gupta, M. McAlary, and A. Fowler-Taylor Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma Ann Allergy Asthma Immunol 91 2003 182 188
    • (2003) Ann Allergy Asthma Immunol , vol.91 , pp. 182-188
    • Berger, W.1    Gupta, N.2    McAlary, M.3    Fowler-Taylor, A.4
  • 42
    • 33645335398 scopus 로고    scopus 로고
    • Long-term omalizumab therapy is well tolerated in children with moderate-to-severe IgE-mediated asthma (abstract)
    • H. Milgrom, T.P. Miller, B. Lanier, A. Fowler-Taylor, H. Chen, and N. Gupta Long-term omalizumab therapy is well tolerated in children with moderate-to-severe IgE-mediated asthma (abstract) Proc Am Thorac Soc 2 2005 A358
    • (2005) Proc Am Thorac Soc , vol.2 , pp. 358
    • Milgrom, H.1    Miller, T.P.2    Lanier, B.3    Fowler-Taylor, A.4    Chen, H.5    Gupta, N.6
  • 43
    • 11144356805 scopus 로고    scopus 로고
    • Efficacy and safety of a recombinant anti-immunoglobulin e antibody (omalizumab) in severe allergic asthma
    • S.T. Holgate, A.G. Chuchalin, J. Hébert, J. Lötvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
    • (2004) Clin Exp Allergy , vol.34 , pp. 632-638
    • Holgate, S.T.1    Chuchalin, A.G.2    Hébert, J.3    Lötvall, J.4    Persson, G.B.5    Chung, K.F.6
  • 44
    • 66149110204 scopus 로고    scopus 로고
    • Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma
    • J. Bousquet, F. Chung, J.M. Tunon-de-Lara, K. Oshinyemi, G. Tran, and H. Fox Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma Allergy 58 suppl 74 2003 A4
    • (2003) Allergy , vol.58 , Issue.SUPPL. 74 , pp. 4
    • Bousquet, J.1    Chung, F.2    Tunon-De-Lara, J.M.3    Oshinyemi, K.4    Tran, G.5    Fox, H.6
  • 45
    • 85009292874 scopus 로고    scopus 로고
    • Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
    • 48S, P421
    • A. Chuchalin, J. Hébert, M. Roli, J. Gao, and C. Reisner Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Eur Respir J 26 suppl 49 2005 48S, P421
    • (2005) Eur Respir J , vol.26 , Issue.SUPPL. 49
    • Chuchalin, A.1    Hébert, J.2    Roli, M.3    Gao, J.4    Reisner, C.5
  • 46
    • 43749098911 scopus 로고    scopus 로고
    • Omalizumab demonstrates long-term asthma control, safety and tolerability in patients with severe immunoglobulin E-mediated allergic asthma
    • K. Chung, S. Holgate, M. Rolli, J. Gao, and C. Reisner Omalizumab demonstrates long-term asthma control, safety and tolerability in patients with severe immunoglobulin E-mediated allergic asthma Allergy 62 suppl 83 2007 210
    • (2007) Allergy , vol.62 , Issue.SUPPL. 83 , pp. 210
    • Chung, K.1    Holgate, S.2    Rolli, M.3    Gao, J.4    Reisner, C.5
  • 47
    • 4444232912 scopus 로고    scopus 로고
    • Effects of treatment with anti-immunoglobulin e antibody omalizumab on airway inflammation in allergic asthma
    • R. Djukanovi, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, and K.F. Chung Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
    • (2004) Am J Respir Crit Care Med , vol.170 , pp. 583-593
    • Djukanovi, R.1    Wilson, S.J.2    Kraft, M.3    Jarjour, N.N.4    Steel, M.5    Chung, K.F.6
  • 49
    • 3042786151 scopus 로고    scopus 로고
    • Efficacy and tolerability of anti-immunoglobulin e therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma
    • J.G. Ayres, B. Higgins, E.R. Chilvers, G. Ayre, M. Blogg, and H. Fox Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma Allergy 59 2004 701 708
    • (2004) Allergy , vol.59 , pp. 701-708
    • Ayres, J.G.1    Higgins, B.2    Chilvers, E.R.3    Ayre, G.4    Blogg, M.5    Fox, H.6
  • 50
    • 33846464598 scopus 로고    scopus 로고
    • Safety of anti-immunoglobulin e therapy with omalizumab in allergic patients at risk of geohelminth infection
    • A.A. Cruz, F. Lima, E. Sarinho, G. Ayre, C. Martin, and H. Fox Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection Clin Exp Allergy 37 2007 197 207
    • (2007) Clin Exp Allergy , vol.37 , pp. 197-207
    • Cruz, A.A.1    Lima, F.2    Sarinho, E.3    Ayre, G.4    Martin, C.5    Fox, H.6
  • 51
    • 3042781547 scopus 로고    scopus 로고
    • Efficacy and tolerability of anti-immunoglobulin e therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
    • A.M. Vignola, M. Humbert, J. Bousquet, L.P. Boulet, S. Hedgecock, and M. Blogg Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
    • (2004) Allergy , vol.59 , pp. 709-717
    • Vignola, A.M.1    Humbert, M.2    Bousquet, J.3    Boulet, L.P.4    Hedgecock, S.5    Blogg, M.6
  • 52
    • 20044362008 scopus 로고    scopus 로고
    • Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
    • M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hébert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
    • (2005) Allergy , vol.60 , pp. 309-316
    • Humbert, M.1    Beasley, R.2    Ayres, J.3    Slavin, R.4    Hébert, J.5    Bousquet, J.6
  • 53
    • 71249102935 scopus 로고    scopus 로고
    • Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
    • B. Lanier, T. Bridges, M. Kulus, A.F. Taylor, I. Berhane, and C.F. Vidaurre Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J Allergy Clin Immunol 124 2009 1210 1216
    • (2009) J Allergy Clin Immunol , vol.124 , pp. 1210-1216
    • Lanier, B.1    Bridges, T.2    Kulus, M.3    Taylor, A.F.4    Berhane, I.5    Vidaurre, C.F.6
  • 54
    • 79953737882 scopus 로고    scopus 로고
    • Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
    • J. Bousquet, Z. Siergiejko, E. Swiebocka, M. Humbert, K.F. Rabe, and N. Smith Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 2011 671 678
    • (2011) Allergy , vol.66 , pp. 671-678
    • Bousquet, J.1    Siergiejko, Z.2    Swiebocka, E.3    Humbert, M.4    Rabe, K.F.5    Smith, N.6
  • 55
    • 80052389968 scopus 로고    scopus 로고
    • Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation
    • G.J. Rivire, C.-M. Yeh, C.V. Reynolds, L. Brookman, and G. Kaiser Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation J Bioequiv Availab 3 2011 144 150
    • (2011) J Bioequiv Availab , vol.3 , pp. 144-150
    • Rivire, G.J.1    Yeh, C.-M.2    Reynolds, C.V.3    Brookman, L.4    Kaiser, G.5
  • 56
    • 84871715560 scopus 로고    scopus 로고
    • High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table
    • O. Kornmann, H. Watz, C. Munzu, S. Koehne-Voss, V. Erpenback, and G. Kaiser High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table Eur Respir J 36 suppl 54 2010 P3997
    • (2010) Eur Respir J , vol.36 , Issue.SUPPL. 54 , pp. 3997
    • Kornmann, O.1    Watz, H.2    Munzu, C.3    Koehne-Voss, S.4    Erpenback, V.5    Kaiser, G.6
  • 57
    • 84862798479 scopus 로고    scopus 로고
    • Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
    • S. Zielen, A. Lieb, J. DeMonchy, S. DelaMotte, F. Wagner, and R. Fuhr Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Eur Respir J 34 suppl 53 2009 E1869
    • (2009) Eur Respir J , vol.34 , Issue.SUPPL. 53 , pp. 1869
    • Zielen, S.1    Lieb, A.2    Demonchy, J.3    Delamotte, S.4    Wagner, F.5    Fuhr, R.6
  • 58
    • 84862781676 scopus 로고    scopus 로고
    • Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation
    • G.J. Rivire, S. Abbi, S. Koehne-Voss, K. Kim, and J.S. Jaffe Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation Eur Respir J 34 suppl 53 2009 E1873
    • (2009) Eur Respir J , vol.34 , Issue.SUPPL. 53 , pp. 1873
    • Rivire, G.J.1    Abbi, S.2    Koehne-Voss, S.3    Kim, K.4    Jaffe, J.S.5
  • 59
    • 84862805574 scopus 로고    scopus 로고
    • Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE mediated) asthma
    • L. Somerville, J. Bardelas, A. Viegas, P. D'Andrea, J. Thirlwell, and M. Massanari Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE mediated) asthma Eur Respir J 34 suppl 53 2009 E1876
    • (2009) Eur Respir J , vol.34 , Issue.SUPPL. 53 , pp. 1876
    • Somerville, L.1    Bardelas, J.2    Viegas, A.3    D'Andrea, P.4    Thirlwell, J.5    Massanari, M.6
  • 60
    • 33846084882 scopus 로고    scopus 로고
    • Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis
    • K. Okubo, S. Ogino, T. Nagakura, and T. Ishikawa Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Allergol Int 55 2006 379 386
    • (2006) Allergol Int , vol.55 , pp. 379-386
    • Okubo, K.1    Ogino, S.2    Nagakura, T.3    Ishikawa, T.4
  • 61
    • 70350444881 scopus 로고    scopus 로고
    • Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma
    • K. Ohta, T. Miyamoto, T. Amagasaki, and M. Yamamoto Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma Respirology 14 2009 1156 1165
    • (2009) Respirology , vol.14 , pp. 1156-1165
    • Ohta, K.1    Miyamoto, T.2    Amagasaki, T.3    Yamamoto, M.4
  • 62
    • 38349133719 scopus 로고    scopus 로고
    • Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis
    • T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi, and T. Ishikawa Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Clin Exp Allergy 38 2008 329 337
    • (2008) Clin Exp Allergy , vol.38 , pp. 329-337
    • Nagakura, T.1    Ogino, S.2    Okubo, K.3    Sato, N.4    Takahashi, M.5    Ishikawa, T.6
  • 63
    • 77954561297 scopus 로고    scopus 로고
    • One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma
    • K. Ohta, M. Yamamoto, N. Sato, K. Ikeda, and T. Miyamoto One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma Allergol Int 2 2010 167 174
    • (2010) Allergol Int , vol.2 , pp. 167-174
    • Ohta, K.1    Yamamoto, M.2    Sato, N.3    Ikeda, K.4    Miyamoto, T.5
  • 64
    • 0036174045 scopus 로고    scopus 로고
    • Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis
    • J. Kuehr, J. Brauburger, S. Zielen, U. Schauer, W. Kamin, and A. Von Berg Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis J Allergy Clin Immunol 109 2002 274 280
    • (2002) J Allergy Clin Immunol , vol.109 , pp. 274-280
    • Kuehr, J.1    Brauburger, J.2    Zielen, S.3    Schauer, U.4    Kamin, W.5    Von Berg, A.6
  • 65
    • 58849143492 scopus 로고    scopus 로고
    • Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
    • M.V. Kopp, E. Hamelmann, S. Zielen, W. Kamin, K.C. Bergmann, and C. Sieder Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma Clin Exp Allergy 39 2009 271 279
    • (2009) Clin Exp Allergy , vol.39 , pp. 271-279
    • Kopp, M.V.1    Hamelmann, E.2    Zielen, S.3    Kamin, W.4    Bergmann, K.C.5    Sieder, C.6
  • 66
    • 79959855552 scopus 로고    scopus 로고
    • Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
    • M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, and S. Seyfried Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase J Allergy Clin Immunol 128 2011 202 209
    • (2011) J Allergy Clin Immunol , vol.128 , pp. 202-209
    • Maurer, M.1    Altrichter, S.2    Bieber, T.3    Biedermann, T.4    Brautigam, M.5    Seyfried, S.6
  • 68
    • 77957168146 scopus 로고    scopus 로고
    • Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma
    • P. Chanez, C. Contin-Bordes, G. Garcia, C. Verkindre, A. Didier, and F. De Blay Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma Respir Med 104 2010 1608 1617
    • (2010) Respir Med , vol.104 , pp. 1608-1617
    • Chanez, P.1    Contin-Bordes, C.2    Garcia, G.3    Verkindre, C.4    Didier, A.5    De Blay, F.6
  • 69
    • 75849151415 scopus 로고    scopus 로고
    • Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
    • M. Massanari, H. Nelson, T. Casale, W. Busse, F. Kianifard, and G.P. Geba Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma J Allergy Clin Immunol 125 2010 383 389
    • (2010) J Allergy Clin Immunol , vol.125 , pp. 383-389
    • Massanari, M.1    Nelson, H.2    Casale, T.3    Busse, W.4    Kianifard, F.5    Geba, G.P.6
  • 72
    • 0030956903 scopus 로고    scopus 로고
    • The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects
    • J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
    • (1997) Am J Respir Crit Care Med , vol.155 , pp. 1828-1834
    • Fahy, J.V.1    Fleming, H.E.2    Wong, H.H.3    Liu, J.T.4    Su, J.Q.5    Reimann, J.6
  • 73
    • 0000746848 scopus 로고    scopus 로고
    • Phase i study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma [abstract]
    • J. Corren, J. Froehlich, J. Schoenhoff, S. Spector, G. Rachelefsky, and H. Schanker Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma [abstract] J Allergy Clin Immunol 97 suppl 1996 245
    • (1996) J Allergy Clin Immunol , vol.97 , Issue.SUPPL. , pp. 245
    • Corren, J.1    Froehlich, J.2    Schoenhoff, J.3    Spector, S.4    Rachelefsky, G.5    Schanker, H.6
  • 74
    • 0033136728 scopus 로고    scopus 로고
    • Down-regulation of human basophil IgE and FC-epsilon-RI-alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo
    • S.S. Saini, D.W. MacGlashan, S.A. Sterbinsky, A. Togias, D.C. Adelman, and L.M. Lichtenstein Down-regulation of human basophil IgE and FC-epsilon-RI-alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo J Immunol 162 1999 5624 5630
    • (1999) J Immunol , vol.162 , pp. 5624-5630
    • Saini, S.S.1    MacGlashan, D.W.2    Sterbinsky, S.A.3    Togias, A.4    Adelman, D.C.5    Lichtenstein, L.M.6
  • 76
    • 79952303048 scopus 로고    scopus 로고
    • A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy
    • H.A. Sampson, D.Y.M. Leung, A.W. Burks, G. Lack, S.L. Bahna, and S.M. Jones A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy J Allergy Clin Immunol 127 2011 1309 1310
    • (2011) J Allergy Clin Immunol , vol.127 , pp. 1309-1310
    • Sampson, H.A.1    Leung, D.Y.M.2    Burks, A.W.3    Lack, G.4    Bahna, S.L.5    Jones, S.M.6
  • 77
    • 79955751312 scopus 로고    scopus 로고
    • Omalizumab in severe allergic asthma inadequately controlled with standard therapy - A randomized trial
    • N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, and J. Zhu Omalizumab in severe allergic asthma inadequately controlled with standard therapy - a randomized trial Ann Intern Med 154 2011 573 582
    • (2011) Ann Intern Med , vol.154 , pp. 573-582
    • Hanania, N.A.1    Alpan, O.2    Hamilos, D.L.3    Condemi, J.J.4    Reyes-Rivera, I.5    Zhu, J.6
  • 78
    • 79551483914 scopus 로고    scopus 로고
    • Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge
    • J. Corren, R.A. Wood, D. Patel, J. Zhu, A. Yegin, and G. Dhillon Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge J Allergy Clin Immunol 127 2011 398 405
    • (2011) J Allergy Clin Immunol , vol.127 , pp. 398-405
    • Corren, J.1    Wood, R.A.2    Patel, D.3    Zhu, J.4    Yegin, A.5    Dhillon, G.6
  • 79
    • 80052299857 scopus 로고    scopus 로고
    • A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
    • e1
    • S. Saini, K.E. Rosen, H.J. Hsieh, D.A. Wong, E. Conner, and A. Kaplan A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol 128 2011 567 573 e1
    • (2011) J Allergy Clin Immunol , vol.128 , pp. 567-573
    • Saini, S.1    Rosen, K.E.2    Hsieh, H.J.3    Wong, D.A.4    Conner, E.5    Kaplan, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.